Disease modeling using iPSCs

We are seeking partners interested in disease cellular modeling using induced pluripotent stem cells (iPSCs) for developing patient-specific cellular models of human disease and investigating disease mechanisms in relevant human cell types. Patient-derived somatic cells can be reprogrammed into iPSCs and subsequently differentiated into disease-relevant lineages, enabling the study of disease-associated phenotypes under controlled experimental conditions. The combination of iPSC technology with CRISPR-based genome editing, whole-genome/exome sequencing, RNA-seq, single-cell sequencing, and other multi-omics approaches allows the generation of genetically defined and isogenic disease models. These systems can be used to investigate molecular mechanisms, identify disease-associated biomarkers and therapeutic targets, and evaluate potential drug responses. The integration of iPSC-based models with genome editing and advanced sequencing technologies could provide an important platform for precision disease modelling, drug discovery, toxicity assessment, and development of personalized therapeutic strategies. This approach is particularly valuable for genetically heterogeneous and complex diseases for which conventional cellular or animal models do not fully reproduce human disease biology.